Canada markets closed

OncoCyte Corporation (OCX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.4000+0.1700 (+5.26%)
At close: 4:00PM EDT
3.4000 0.00 (0.00%)
After hours: 04:00PM EDT

OncoCyte Corporation

15 Cushing
Irvine, CA 92618
United States
949 409 7600
http://oncocyte.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees51

Key Executives

NameTitlePayExercisedYear Born
Mr. Ronald A. Andrews Jr.CEO, Pres & Director978.35kN/A1960
Mr. Mitchell S. LevineChief Financial Officer509.23kN/AN/A
Ms. Padma SundarChief Commercial Officer365.22kN/AN/A
Ms. Gisela A. PaulsenChief Operating OfficerN/AN/AN/A
Ms. Li YuVP, Controller & Principal Accounting OfficerN/AN/AN/A
Mr. William AnnettAdvisorN/AN/A1954
Dr. Douglas T. Ross M.D., Ph.D.Chief Science OfficerN/AN/AN/A
Mr. Robert S. SeitzHead of Immune OncologyN/AN/A1964
Dr. Michael D. WestScientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc.N/AN/A1953
Ms. Sara RiordanDirector of Medical EducationN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides custom drug target discovery; assay design, development, and validation; and clinical trial and other testing services for pharmaceutical companies. OncoCyte Corporation has a strategic collaboration with Gruppo Oncologico del Nord-Ovest of Pisa to evaluate DetermaIO as a biomarker for immunotherapy response in metastatic colorectal cancer; and Echelon Diagnostics, Inc. The company was founded in 2009 and is headquartered in Irvine, California.

Corporate Governance

OncoCyte Corporation’s ISS Governance QualityScore as of September 26, 2021 is 4. The pillar scores are Audit: 9; Board: 6; Shareholder Rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.